[go: up one dir, main page]

BR0014003A - Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra - Google Patents

Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra

Info

Publication number
BR0014003A
BR0014003A BR0014003-1A BR0014003A BR0014003A BR 0014003 A BR0014003 A BR 0014003A BR 0014003 A BR0014003 A BR 0014003A BR 0014003 A BR0014003 A BR 0014003A
Authority
BR
Brazil
Prior art keywords
sufonil
urea
compounds
combination treatment
diaryl
Prior art date
Application number
BR0014003-1A
Other languages
English (en)
Inventor
Bruce Henry Littman
Thasia Louise Goodwi Woodworth
Mark Anthony Dombroski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0014003A publication Critical patent/BR0014003A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "TRATAMENTO DE COMBINAçãO COM COMPOSTOS DE DIARIL SUFONIL URéIA E IL-1RA". A invenção refere-se com métodos e composições para tratar e prevenir estados de doença mediados pela interleucina 1 (IL-1). Os métodos e composições utilizam um polipeptídeo antagonista do receptor da interleucina 1 (IL-1 ra) ou uma variante deste em combinação com um agente não esteroidal de inibição do processamento e liberação de IL-1.
BR0014003-1A 1999-09-14 2000-08-28 Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra BR0014003A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14
PCT/IB2000/001192 WO2001019390A1 (en) 1999-09-14 2000-08-28 Combination treatment with il-1ra and diaryl sulphonyl urea compounds

Publications (1)

Publication Number Publication Date
BR0014003A true BR0014003A (pt) 2002-05-21

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014003-1A BR0014003A (pt) 1999-09-14 2000-08-28 Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra

Country Status (13)

Country Link
EP (1) EP1214087A1 (pt)
JP (1) JP2003509378A (pt)
AR (1) AR033650A1 (pt)
AU (1) AU6464400A (pt)
BR (1) BR0014003A (pt)
CA (1) CA2383026A1 (pt)
CO (1) CO5190701A1 (pt)
EC (1) ECSP003652A (pt)
GT (1) GT200000155A (pt)
PA (1) PA8502901A1 (pt)
PE (1) PE20010685A1 (pt)
TN (1) TNSN00183A1 (pt)
WO (1) WO2001019390A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
PT3259253T (pt) * 2015-02-16 2020-03-11 Univ Queensland Sulfonilureias e compostos relacionados e uso dos mesmos
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
WO2017184623A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
EP3851434A1 (en) 2017-01-23 2021-07-21 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
JP7072586B2 (ja) 2017-05-24 2022-05-20 ザ ユニバーシティ オブ クィーンズランド 新規な化合物及び使用
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
HUE057414T2 (hu) 2017-07-07 2022-05-28 Inflazome Ltd Új szulfonamid karboxamid vegyületek
CA3068836A1 (en) 2017-07-24 2019-01-31 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
BR112020003014A2 (pt) 2017-08-15 2020-07-28 Inflazome Limited sulfonilureias e sulfoniltioureias como inibidores de vnlrp3
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759078A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CN112584899A (zh) 2018-07-03 2021-03-30 诺华股份有限公司 Nlrp调节剂
AU2019306658A1 (en) 2018-07-20 2021-01-07 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
SG11202012159TA (en) 2018-07-20 2021-01-28 Hoffmann La Roche Sulfonylurea compounds as inhibitors of interleukin-1 activity
MX2021001754A (es) 2018-08-15 2021-04-19 Inflazome Ltd Compuestos de sulfonamidaurea novedosos.
US20230011652A1 (en) * 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
PL3911631T3 (pl) 2019-01-14 2025-04-28 Zydus Lifesciences Limited Nowe podstawione pochodne sulfonylomocznika
CA3171969A1 (en) * 2020-05-25 2021-12-02 Beijing Vdjbio Co., Ltd. An interleukin-1 receptor antagonist and a fusion protein containing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
PT964849E (pt) * 1997-01-29 2003-08-29 Pfizer Derivados de sulfonilureia e sua utilizacao no controlo da actovidade da interleucina-1
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
PA8502901A1 (es) 2002-02-21
JP2003509378A (ja) 2003-03-11
CO5190701A1 (es) 2002-08-29
AR033650A1 (es) 2004-01-07
PE20010685A1 (es) 2001-07-03
WO2001019390A1 (en) 2001-03-22
GT200000155A (es) 2002-03-08
TNSN00183A1 (fr) 2005-11-10
ECSP003652A (es) 2002-04-23
CA2383026A1 (en) 2001-03-22
EP1214087A1 (en) 2002-06-19
AU6464400A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
BR0014384A (pt) Compostos para o tratamento da isquémia
BR0213817A (pt) Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
EP1539234A4 (en) METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR9808948A (pt) Composição de confeitaria
BR9911666A (pt) Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica
BRPI0013478B8 (pt) medicamento compreendendo inibidor pde e uso de roflumilast
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BR9811556A (pt) Terapia de combinação compreendendo atorvastatina e um agente anti-hipertensivo
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.